Cyclic ketone inhibitors of the cysteine protease cathepsin K

Journal of Medicinal Chemistry

Volumn 44, Issue 5, 2001, Pages 725-736

  Marquis, R W ^a   Ru, Y ^a   Zeng, J ^a   Lee Trout, R E ^a   LoCastro, S M ^a   Gribble, A D ^b   Witherington, J ^b   Fenwick, A E ^b   Garnier, B ^b   Tomaszek, T ^c   Tew, D ^c   Hemling, M E ^d   Quinn, C J ^d   Smith, W W ^e   Zhao, B ^e   McQueney, M S ^f   Janson, C A ^f   D'Alessio, K ^f   Veber, D F ^a  

^a Departments of Medicinal Chemistry   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

^c Molecular Recognition   (United States)

^d Physical and Structural Chemistry   (United States)

^e SmithKline Beecham Pharmaceutical   (United States)

^f Protein Biochemistry   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMIDOPYRROLIDIN 4 ONE DERIVATIVE; ACETAL; CATHEPSIN K; CYSTEINE PROTEINASE; CYSTEINE PROTEINASE INHIBITOR; EPIMERASE; KETONE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CRYSTAL STRUCTURE; CRYSTALLOGRAPHY; DIASTEREOISOMER; ENZYME INHIBITION; OSTEOCLAST; OSTEOPOROSIS; PROTEIN EXPRESSION; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ANIMALS; BINDING SITES; CATHEPSINS; CHROMATOGRAPHY, LIQUID; CRYSTALLOGRAPHY, X-RAY; ENZYME INHIBITORS; FURANS; HUMANS; KETONES; MASS SPECTROMETRY; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PIPERIDINES; PYRANS; PYRROLIDINONES; RATS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0035282807     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm000320t     Document Type: Article

References (72)

1. Cysteine proteases: Evolution, function and inhibitor design
2. Emerging roles for cysteine proteases in human biology
3. Proteinases in inflammation
4. The role of proteolytic enzymes in brain tumor infiltration
5. The cysteine protease cathepsin B in cancer
6. Cruzipain, the major cysteine proteinase from the protazoan parasite Trypanosoma cruzi
7. Cysteine proteases of parasites: A remarkable diversity of function
8. The proteases and pathogenicity of parasitic protazoa
9. Development of cysteine protease inhibitors as chemotherepy for parasitic diseases: Insights on safety, target validation, and mechanism of action
10. Inhibition of cathepsin K-a novel approach to antiresorptive therapy
11. Cathepsin K, but not cathepsins B, L or S is abundantly expressed in human osteoclasts
12. Human cathepsin O2, a novel cysteine protease highly expressed in osteoclastomas and ovary. Molecular cloning, sequencing and tissue distribution
13. Molecular cloning of human cathepsin O, a novel endoproteinase and homologue of rabbit OC2
14. Localization of cathepsin K in human osteoclasts by In Situ hybridization and immunohistochemistry
15. Proteolytic activity of human osteoclast cathepsin K. Expression, activation and substrate identification
16. Cathepsin K; isolation and characterization of the murine cDNA and genomic sequence, the homologue of the human pycnodysostosis Gene
17. A nonsense mutation in the cathepsin K gene observed in a family with pycnodysostosis
18. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency
19. Cathepsin K antisense oligodeoxy-nucleotide inhibits osteoclastic bone resorption
20. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin K deficient mice
21. Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization
22. Small synthetic inhibitors of cysteine proteases
23. Cysteine proteases and their inhibitors
24. Protease inhibitors: Current status and future prospects
25. Structural basis of the inhibition of cysteine proteases by E-64 and its derivatives
26. New inhibitors of cysteine proteases. Peptidyl acyloxymethyl ketones and the quiescent nucleofuge strategy
27. Some thoughts on enzyme inhibition and the quiescent affinity label concept
28. Peptidyl(acyloxy)methanes as quiescent affinity labels for cysteine proteases
29. Vinyl sulfones as mechanism-based cysteine protease inhibitors
30. Peptidyl vinyl sulphones: A new class of potent and selective cysteine protease inhibitors
31. Crystal structure of human cathepsin K complexed with a potent inhibitor
32. Vinylogous amino acid esters: A new class of inactivators for thiol proteases
33. Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes
34. Peptide aldehyde inhibitors of cathepsin K inhibit bone resorption both in vitro and in vivo
35. Synthesis of peptide aldehyde derivatives as selective inhibitors of human cathepsin L and their inhibitory effect on bone resorption
36. Conformationally constrained inhibitors of caspase-1 (interleukin-1β converting enzyme) and of the human CED-3 homologue caspase-3 (CPP32, apopain)
37. A new class of proteinase inhibitor. Cyclopropenone-containing inhibitor of papain
38. Cyclopropeneone-containing cysteine proteinase inhibitors. Synthesis and enzyme inhibitory activities
39. 13C NMR evidence for a thioimidate ester adduct
40. Benzoylamidoacetonitrile is bound as a thioimidate in the active site of papain
41. Inhibition of papain by nitriles: Mechanistic studies using NMR and kinetic measurements
42. Inhibition of cathepsin B and papain by peptidyl α-keto esters, α-keto amides α-diketones and α-keto acids
43. Peptide α-keto ester, α-keto amide, and α-keto acid inhibitors of calpains and other cysteine proteases
44. Stereospecific synthesis of peptidyl α-keto amides as inhibitors of calpain
45. Activated ketones as potent reversible inhibitors of interleukin-1β converting enzyme
46. Structure and design of potent and selective cathepsin K inhibitors
47. Use of X-ray cocrystal structures and molecular modeling to design potent and selective non-peptide inhibitors of cathepsin K
48. Potent dipeptidyl ketone inhibitors of the cysteine protease cathepsin K
49. Design and synthesis of thrombin inhibitors
50. Inhibitors of thrombin containing arginine ketone derivatives
51. Thrombin inhibitors based on ketone derivatives of arginine and lysine
52. On the size of the active site in proteases I. Papain
53. Conformationally constrained 1,3-diamino ketones: A series of potent and selective inhibitors of the cysteine protease cathepsin K
54. Regio- and stereoselectivity of the three-membered ring opening of 3,4-epoxytetrahydropyrans and of the corresponding epibromonium ions
55. Sulfur trioxide in the oxidation of alcohols by dimethyl sulfoxide
56. Synthesis and protein kinase C activities of balanol analogues with modification of the 4-hydroxbenzamido moiety
57. Enzyme inhibitors: Ground state/transition state analogues
58. Transition-state analogues in drug design
59. Recent developments in the field of enzyme inhibitors
60. Transition state analogues as enzyme inhibitors
61. Transition state and multisubstrate analogue inhibitors
62. Diastereoselective synthesis, activity and chiral stability of cyclic alkoxy ketone inhibitors of cathepsin K
63. Solid-phase synthesis of cyclic alkoxy ketones, inhibitors of the cysteine protease cathepsin K
64. The nature of π-π interactions
65. Using the electrostatic field effect to design a new class of inhibitors for cysteine proteases
66. Synthesis of cyclohexanone-based cathepsin B inhibitors that interact with both the S and S' binding sites
67. Simultaneous pharmacokinetic screening of a mixture of compounds in the dog using API LC/MS/MS analysis for increased throughput
68. Crystal structure of human osteoclast cathepsin K complex with E-64